Neuropathic pain and psychological morbidity in patients with treated leprosy: A cross-sectional prevalence study in Mumbai

PLoS Neglected Tropical Diseases

Volumn 5, Issue 3, 2011, Pages

  Lasry Levy, Estrella ^a   Hietaharju, Aki ^b   Pai, Vivek ^c   Ganapati, Ramaswamy ^c   Rice, Andrew S C ^d   Haanpää, Maija ^e,f   Lockwood, Diana N J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c Bombay Leprosy Project   (India)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f Rehabilitation ORTON   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; PREDNISOLONE; THALIDOMIDE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GENERAL HEALTH QUESTIONNAIRE; HUMAN; HYPESTHESIA; INDIA; LEPROSY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORBIDITY; NEUROPATHIC PAIN; NEUROPSYCHOLOGICAL TEST; PAIN ASSESSMENT; PARESTHESIA; PREVALENCE; SENSITIVITY AND SPECIFICITY; SKIN DEFECT; SKIN TINGLING; EVALUATION; MIDDLE AGED; NEURALGIA; PATHOLOGY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LEPROSY; MALE; MENTAL DISORDERS; MIDDLE AGED; NEURALGIA; QUESTIONNAIRES; YOUNG ADULT;

EID: 79953776812     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000981     Document Type: Article

References (39)

1. Britton WJ, Lockwood DN, (2004) Leprosy. Lancet 363: 1209-1219.
2. (2008) Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec 83: 293-300.
3. Walker SL, Lockwood DN, (2008) Leprosy type 1 (reversal) reactions and their management. Lepr Rev 79: 372-386.
4. Scollard DM, (2008) The biology of nerve injury in leprosy. Lepr Rev 79: 242-253.
5. IASP, (1994) Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. In: Merskey H, Bogduk N, editors. Task Force on Taxonomy of the IASP. 2nd ed Seattle IASP Press.
6. Haanpaa M, Attal N, Backonja M, Baron R, Bennett M, et al. (2010) NeuPSIG guidelines on neuropathic pain assessment. Pain.
7. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, et al. (2008) Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70: 1630-1635.
8. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, et al. (2005) Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114: 29-36.
9. Stump PR, Baccarelli R, Marciano LH, Lauris JR, Teixeira MJ, et al. (2004) Neuropathic pain in leprosy patients. Int J Lepr Other Mycobact Dis 72: 134-138.
10. Saunderson P, Bizuneh E, Leekassa R, (2008) Neuropathic pain in people treated for multibacillary leprosy more than ten years previously. Lepr Rev 79: 270-276.
11. Lund C, Koskinen M, Suneetha S, Lockwood DN, Haanpaa M, et al. (2007) Histopathological and clinical findings in leprosy patients with chronic neuropathic pain: a study from Hyderabad, India. Lepr Rev 78: 369-380.
12. Senturk V, Sagduyu A, (2004) [Psychiatric disorders and disability among leprosy patients; a review]. Turk Psikiyatri Derg 15: 236-243.
13. Senturk V, Stewart R, Sagduyu A, (2007) Screening for mental disorders in leprosy patients: comparing the internal consistency and screening properties of HADS and GHQ-12. Lepr Rev 78: 231-242.
14. Tsutsumi A, Izutsu T, Akramul Islam MD, Amed JU, Nakahara S, et al. (2004) Depressive status of leprosy patients in Bangladesh: association with self-perception of stigma. Lepr Rev 75: 57-66.
15. Daniel HC, Narewska J, Serpell M, Hoggart B, Johnson R, et al. (2008) Comparison of psychological and physical function in neuropathic pain and nociceptive pain: implications for cognitive behavioral pain management programs. Eur J Pain 12: 731-741.
16. ICD9Data.com (2008) Available at: http://www.icd9data.com/2008/Volume1/290-319/300-316/300/300.9.htm.
17. Benjamin S, Lennon S, Gardner G, (1991) The validity of the General Health Questionnaire for first-stage screening for mental illness in pain clinic patients. Pain 47: 197-202.
18. Hietaharju A, Croft R, Alam R, Birch P, Mong A, et al. (2000) Chronic neuropathic pain in treated leprosy. Lancet 356: 1080-1081.
19. Bennett MI, Bouhassira D, (2007) Epidemiology of neuropathic pain: can we use the screening tools? Pain 132: 12-13.
20. Dieleman JP, Kerklaan J, Huygen FJ, Bouma PA, Sturkenboom MC, (2008) Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 137: 681-688.
21. Bharucha NE, Bharucha AE, Bharucha EP, (1991) Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology 41: 1315-1317.
22. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, et al. (2005) Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 30: 374-385.
23. (1998) WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser 874: 1-43.
24. Ridley DS, (1988) Pathogenesis of Leprosy and Related Diseases. London Wright.
25. (2006) WHO global strategy for further reducing the leprosy burden and sustaining leprosy control activities (Plan period: 2006-2010). Indian J Lepr 78: 7-31.
26. van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, et al. (2005) The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev 76: 14-34.
27. Pradeepa R, Rema M, Vignesh J, Deepa M, Deepa R, et al. (2008) Prevalence and risk factors for diabetic neuropathy in an urban south Indian population: the Chennai Urban Rural Epidemiology Study (CURES-55). Diabet Med 25: 407-412.
28. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, et al. (2006) The burden of Herpes Zoster: a prospective population based study. Vaccine 24: 1308-1314.
29. Smyth K, Affandi JS, McArthur JC, Bowtell-Harris C, Mijch AM, et al. (2007) Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med 8: 367-373.
30. Van Brakel WH, Saunderson P, Shetty V, Brandsma JW, Post E, et al. (2007) International workshop on neuropathology in leprosy--consensus report. Lepr Rev 78: 416-433.
31. Jain S, Visser LH, Praveen TL, Rao PN, Surekha T, et al. (2009) High-resolution sonography: a new technique to detect nerve damage in leprosy. PLoS Negl Trop Dis 3: e498.
32. Martinoli C, Derchi LE, Bertolotto M, Gandolfo N, Bianchi S, et al. (2000) US and MR imaging of peripheral nerves in leprosy. Skeletal Radiol 29: 142-150.
33. von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, Hoffmann F, Naumann R, et al. (2008) A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 81: 247-252.
34. Walker SL, Waters MF, Lockwood DN, (2007) The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 78: 197-215.
35. Unal-Cevik I, Sarioglu-Ay S, Evcik D, (2010) A Comparison of the DN4 and LANSS Questionnaires in the Assessment of Neuropathic Pain: Validity and Reliability of the Turkish Version of DN4. J Pain.
36. ITC (2010) Review of leprosy research evidence (2002-2009) and implications for current policy and practice. Lepr Rev 81: 228-275.
37. Wright E, Brew B, Arayawichanont A, Robertson K, Samintharapanya K, et al. (2008) Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology 71: 50-56.
38. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, et al. (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132: 237-251.
39. Garbino JA, Nery JA, Virmond M, Stump PRN, Baccarelli R, et al. (2003) Hanseniase: Diagnostico e tratamento da neuropatia. Projeto Diretrizes, Associacao Medica Brasileira e Conselho Federal de Medicina pp. 147-159.